[CAS NO. 1916571-90-8] NCT-503
PRODUCTS SPECIFICATIONS [1916571-90-8]
DESCRIPTION [1916571-90-8]
Overview
| MDL | MFCD30343875 |
|---|---|
| Molecular Weight | 408.48 |
| Molecular Formula | C20H23F3N4S |
| SMILES | S=C(N1CCN(CC2=CC=C(C(F)(F)F)C=C2)CC1)NC3=NC(C)=CC(C)=C3 |
11 Publications Citing Use of MCE
- [1]Cell Res. 2022 Feb 1.
- [2]Immunity. 2021 Aug 10;54(8):1728-1744.e7.
- [3]Mol Cell. 2019 Sep 19;75(6):1147-1160.e5.
- [4]Nat Metab. 2021 Oct 18.
- [5]Nat Commun. 2019 Jun 20;10(1):2701.
- [6]J Clin Invest. 2020 Jun 1;130(6):3253-3269.
- [7]Cancer Res. 2021 Mar 15;81(6):1443-1456.
- [8]Br J Haematol. 2020 Jul;190(1):52-66.
- [9]Lab Invest. 2021 Oct 8.
- [10]Onco Targets Ther. 2020 May 29;13:4833-4842.
- [11]Chem Pap. 2020 May.
Summary
NCT-503 is a phosphoglycerate dehydrogenase ( PHGDH ) inhibitor with an IC 50 of 2.5 µM.
IC50 & Target
IC50: 2.5 µM (PHGDH) [1]
In Vitro
Human phosphoglycerate dehydrogenase (PHGDH) catalyzes the first, rate-limiting step in the canonical glucose-derived serine synthesis pathway. NCT-503, a PHGDH inhibitor, inhibits serine synthesis from 3-phosphoglycerate in cells (IC 50 =2.5 µM). NCT-503 is inactive against a panel of other dehydrogenases and shows minimal cross-reactivity in a panel of 168 GPCRs. Competition studies of NCT-503 against 3-phosphoglycerate (3-PG) and the co-substrate NAD + reveal a non-competitive mode of inhibition with respect to both 3-PG and NAD + . NCT-503 has EC 50 s of 8–16 µM for the PHGDH-dependent cell lines, a 6- to 10-fold higher EC 50 for MDA-MB-231 cells, and no toxicity towards other PHGDH-independent cell lines [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
NCT-503 exhibits favorable absorption, distribution, metabolism and excretion (ADME) properties. NCT-503 has good exposure, half-life (2.5 hr) and C max (20 µM in plasma) following intraperitoneal administration with significant partitioning into the liver and brain. NCT-503 treatment reduces the growth and weight of PHGDH-dependent MDA-MB-468 xenografts but does not affect the growth or weight of PHGDH-independent MDA-MB-231 xenografts [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 122.41 mM ; Need ultrasonic)
Ethanol : 13.33 mg/mL ( 32.63 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4481 mL | 12.2405 mL | 24.4810 mL |
| 5 mM | 0.4896 mL | 2.4481 mL | 4.8962 mL |
| 10 mM | 0.2448 mL | 1.2241 mL | 2.4481 mL |
-
1.
Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 10 mg/mL (24.48 mM); Suspended solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution
-
4.
Add each solvent one by one: 0.5% methylcellulose >> 0.2% Tween 80
Solubility: 2 mg/mL (4.90 mM); Suspended solution; Need ultrasonic